On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for ...
Analysts have set 12-month price targets for Chimerix, revealing an average target of $9.75, a high estimate of $11.00, and a low estimate of $6.00. Consistency is reflected as the current average ...
Option chain shows key data for Chimerix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ...
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...
StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX – Get Free Report) in a research note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s ...
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results